22:07 , Aug 13, 2019 |  BC Extra  |  Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

Fabrice Chouraqui will step down as president of Novartis Pharmaceuticals U.S. at the end of August. Novartis AG (NYSE:NVS; SIX:NOVN) said he will be succeeded by 14-year Novartis veteran Victor Bulto, who is VP and...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
00:19 , Mar 7, 2018 |  BC Extra  |  Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
20:18 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Aveo reports Phase I data for ficlatuzumab in SCCHN

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 12 evaluable patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who were refractory to cetuximab in a Phase I trial showing that...
20:17 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Aveo reports Phase I data for ficlatuzumab in AML

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) reported data from 8 evaluable patients with relapsed or refractory acute myelogenous leukemia (AML) in a Phase I trial showing that IV ficlatuzumab (AV-299) plus high-dose IV cytarabine led to 4...
19:57 , Jan 13, 2017 |  BC Week In Review  |  Company News

Biodesix, Bioyong deal

Biodesix granted Bioyong rights to develop and commercialize in Taiwan and China, including Macau and Hong Kong, a version of Biodesix’s VeriStrat that will run on Bioyong's mass spectrometry technology. The deal includes an option...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Financial News

Biodesix financial update

Biodesix Inc. , Boulder, Colo.   Business: Diagnostic   Date announced: 2016-07-27   Note: Biodesix raised $7 million in an extension of a series F round, bringing the total raised in the round to $29...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Financial News

Biodesix completes venture financing

Biodesix Inc. , Boulder, Colo.   Business: Diagnostic   Date completed: 2016-02-24   Type: Venture financing   Raised: $22 million   Investor: Existing investors   Note: Biodesix raised $22 million in an undisclosed combination of...
01:07 , Feb 25, 2016 |  BC Extra  |  Financial News

Biodesix raises $22M in series F

Molecular diagnostics company Biodesix Inc. (Boulder, Colo.) said it raised $22 million in a series F round from undisclosed investors. Existing investors provided the majority of the funds. The company said it would develop new...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Biodesix, Aetna sales and marketing update

Aetna issued a positive coverage decision for Biodesix’s blood-based proteomic test VeriStrat for advanced non-small cell lung cancer (NSCLC) patients without EGFR and anaplastic lymphoma kinase (ALK) mutations. Biodesix said the decision increases the number...